IMMU


Immunomedics, Inc. (IMMU): Analyst Phil Nadeau Provides Update From San Antonio Breast Cancer Symposium

Immu-132 continues to have strong efficacy in centrally-reviewed data at SABCS, says Cowen’s Phil Nadeau.

Valeant Pharmaceuticals Intl Inc’s Glaucoma Drug Could Be A Blockbuster, Immunomedics, Inc.’s Breast Cancer Drug Potential Significantly Undervalued

Valeant’s Good News- Manufacturing Qualms Could Be Put at Rest Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has revealed the FDA’s confirmed intention to issue …

Company Update (NASDAQ:IMMU): Here’s Why Immunomedics, Inc. Shares Are Falling 27%

Immunomedics, Inc. (NASDAQ:IMMU) announced that it has priced an underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to …

Analysts Weigh In On Two Falling Biotechs: Adamis Pharmaceuticals Corp (ADMP), Immunomedics, Inc. (IMMU)

Analysts are weighing in on biotech firms Adamis Pharmaceuticals Corp (NASDAQ:ADMP) and Immunomedics, Inc. (NASDAQ:IMMU), as shares of both companies fell sharply today due to …